Addressing Root Causes of Brain Disorders with Innovative Therapeutics

Neuroscience is a complex market encompassing a range of neurological conditions.

- Ayesha Siddiqui

Drug research and development for diseases related to the nervous system has always been challenging. While the oncology sector has seen remarkable progress with new therapies, neuroscience has historically lagged in providing effective cures or treatments for symptoms. However, there is now promising progress in understanding the intricate biology of these conditions and identifying new drug targets. A wave of novel late-stage candidates is advancing through the development pipeline, offering hope for treating serious Central Nervous System (CNS) disorders and entering the market. Recent highprofile approvals, such as Eisai's Leqembi for Alzheimer's and Eli Lilly's Kisunla (donanemab-azbt) for the same condition, have significantly bolstered the morale of firms dedicated to developing neurological treatments. The neuroscience sector is suddenly back in action, with pharma companies renewing their interest, spurred by recent US FDA approvals in neurodegenerative diseases like Alzheimer's. This renewed focus has catapulted neuroscience into one of the most sought-after areas. Let's explore the latest developments in detail.

The global CNS disorders market, in 2022, was valued at $116 billion, ranking it as the fourth largest therapy area behind oncology ($189 billion), immunology ($138 billion), and diabetes ($134 billion). Looking ahead, with ongoing improvements in CNS innovation, growth is expected to accelerate. This growth trajectory could potentially expand the CNS market to between $147 billion and $169 billion globally by 2027. In the APAC region, China's CNS market is anticipated to reach $19.9 billion by 2030. Japan, on the other hand, is expected to grow at a rate of 5.5 per cent from 2022 to 2030, according to an IQVIA report.